Optical News

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 171,900 shares of the company’s common stock to 3 new employees (the...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase announced the first patient was treated in a U.S. IDE clinical trial evaluating its femtosecond laser trabeculotomy procedure for glaucoma....

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the “Special Meeting”) at STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) to remove three directors from the Company’s Board of Directors (the “Board”). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose th...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and...

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced participation in an upcoming investor conference. The Company’s lead investigational asset, BRIMOCHOL™ PF, is designed to be the first and only combination therapy for presbyopia and has received a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. Tenpoint Therapeutic...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis' Byooviz PFS gains European approval....

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the Morgan Stanley Global Consumer & Retail Conference on Wednesday, December 3, 2025, at 11:45 a.m. Eastern Time. A live webcast of the presentation can be accessed in the “Investors” section of the Company’s website at www.ir.nationalvision.com. The webcast will be archived and available on the website shortly after the...

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the pr...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its 5th Annual Ophthalmology Day will take place on Monday, December 1, 2025. The virtual, one-day event will include thematic panel discussions and one-on-one meetings. The event will be hosted by: Ryan Zimmerman, BTIG Medical Technology Analyst Julian Harrison, BTIG Biotechnology Analyst Thomas Shrader, PhD, CFA, BTIG Biotechnology Analyst Justin Zelin, BTIG Biotechnology Analyst Jeet Mukherjee, BTIG Biotechnology Analyst “We are proud to c...

MILAN--(BUSINESS WIRE)--On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies: AAVB-...